"Slim when you get a needle", GLP-1 weight loss pill starts

At 24 weeks, 230 subjects were reduced by an average weight loss of 12.6%.

On June 8th, Mazdutide, jointly developed by Cinda Bio and Lilly Lilly, announced the clinical results of Phase II: Three groups of different dosage types of subjects, injecting once a week, can not only reduce weight, but also improve the waist circumference. , Blood lipids, blood pressure, blood uric acid, liver enzymes and liver fat content.

This is a dual-target drug in high-blood glucose-1 (GLP-1). It is currently the hottest target in the weight loss market.

In 2014, Novo first developed the first generation of GLP-1-1-like Ira-like peptide in the world for the indications for weight loss. Leralugin has become the representative of the new generation of diet pills and brings the gospel to global obesity patients. Competitors saw the huge market advantages of GLP-1 agonist. While the patent of Lichellated compounds is about to expire, with the advancement of technology, similar weight loss drugs have been developed.

The dual-target GLP-1 drug developed by Lilly is one of them. Of course, Nuo and Nord have already prepared the rear hand, and in 2021, the second-generation GLP-1 agonist "Smeglugin" was launched. Lili Lili is currently facing a situation of "head -to -head" clinical trials with Smeglugin.

After Li Lili, domestic pharmaceutical companies such as Cinda, Hengrui, East China Pharmaceuticals followed the development of GLP-1 drugs, and the nobles such as Aimei Keke also participated. Special effect weight loss pills have been smoky, and the market in the next two years is destined to have a peak confrontation.

You can develop a weight loss medicine for weight loss pills with a shot

Speaking of weight loss, I know that I need to "hold my mouth and open my legs." But it is always simple to say, it is difficult to do.

According to statistics from the World Health Organization, nearly 2 billion people in the world are overweight or obese, and as high as 2.8 million due to overweight or obesity. However, for the treatment of obesity, most of the auxiliary intervention of exercise+diet, and the older generation of weight loss pills represented by Sibuquming, which are represented by Sibuquming, have been banned from using it for serious side effects.

Until 2014, the development of new indications of the GLP-1 agonist agent entered a new round of R & D pills.

GLP-1 is a hormone that is mainly produced by intestinal L cells. It is widely distributed in multiple organs and tissues throughout the body. It can promote the secretion of insulin in the body and reduce blood sugar. Blood glucose decreases, energy consumption, and the weight naturally comes down.

Nuo and Nord's Liculite successfully transformed from a kind of lower blood sugar drug to weight loss pills. According to the Phase III clinical trial data of Novo, after 56 weeks, about 62%of obese patients 'weight decreased by 5%, and 34%of patients' weight decreased by 10%.

You don't need to "exercise+control diet", as long as you get a regular injection and persist for a year, your weight can be quickly lost? This has become a reality. For many people with unstable willpower, the emergence of a new generation of weight loss pills is simply a gospel. Moreover, there is no other obvious discomfort except for normal diarrhea and constipation.

Novo Nord has obtained huge business opportunities with Licaramel peptide on the development of weight loss indications. However, happy time is always short. The compound patent of Lichellated peptides failed from 2022 to 2023. At present, various domestic pharmaceutical companies are rubbing their fists to seize the generic drug market.

On June 23, East China Pharmaceutical and Middle East pharmaceutical company Julphar reached a strategic cooperation. JulPhar will obtain two indications: Riraru peptide injection and weight loss of East China Pharmaceuticals, which are developed, produced and commercialized in the development, production and commercialization of 17 countries such as the Middle East and North Africa countries in the UAE, Saudi Arabia, Egypt, and Kuwait. East China Pharmaceutical disclosed that the weight -loss indications of Liculutic peptide have also completed the phase III clinical in China. It is expected to submit a listing application at the end of June this year.

In addition, many domestic pharmaceutical companies such as Renhui Biological, Wanbang Biological, Cinda Bio, East Sunshine, and Housen have been deployed. Some develop Licula-peptide imitation pharmaceuticals, and some develop other GLP-1 agonists.

Many pharmaceutical companies seize the opportunity to enter the era of dual target

The Jianzhi Bureau was informed that the GLP-1 drugs currently in the clinical stage are mostly single targets, and the dual/triple excitement agents such as GLP-1R, GIPR, GCGR and other targets have more clinical advantages. Essence

At present, the Tirzepatide of Lilly is the fastest double target GLP-1 drug in clinical research and development, and has entered the stage III trial stage. According to the clinical data of the third phase of overseas announced by Lilly, Tirzepatide won the average weight of 5mg, 10mg, and 15mg in 72 weeks in the first test with Smeglugin. %, 22.5%.

The clinical results of the stages of Smegutan peptide disclosed by Nond Nord, the average weight of the subject was reduced by 14.9%. In intuitive, Tirzepatide is indeed better than Smeglugan peptide. However, whether it can be approved in the end depends on the attitude of drug supervision agencies in various countries, and the market results are not known.

But anyway, the upgrade of GLP-1 agonists is already a trend. The better development efficacy and longer-lasting preparations will become the future direction. Novo, Lilly, Cinda Bio, Bollinger Yinghan, and the first -time injection of the breeds for the research for Darchia have been performed once a week. Essence

Most of these varieties are in the clinical research stage. At present, the GLP-1 agonist weight loss pills that have been approved worldwide are only Norratic peptides and Smegugi peptides in Nord and Nord. China has no GLP-1 agonist weight loss pills. In the domestic market, the product application of Renhui Biological, East China Pharmaceutical, Wanbang Biochemical, Nuo and Nuo, and Lili Lisin is in the phase III or reporting stage. The Beinugan peptide of Renhui was declared to be listed in March this year, and it is expected to become the first domestic weight loss innovation medicine.

There is a prerequisite for weight loss Most people have misunderstandings

How big will the market for weight loss pills?

The financial report in 2021 shows that the revenue of Nuo and Nord's Litu peptide and Smeglugin on weight loss indications is US $ 1.286 billion. When it reaches 50%, the market performs strong.

On the whole, GLP-1 agonist is growing at high speed, with a compound growth rate of 39.7%, which is higher than the growth rate of 14.4%of insulin and 11.7%of oral hypoglycemic drugs. Accelerate replacement.

GLP-1 agonists such as Liculugin can be used to lose weight. Of course, people who are troubled by obese are expected to "get injections to lose weight" quickly. However, many medical experts remind the public that they must be used under the guidance of professional doctors according to the approved indications.

A person with a pharmacy department of the Three Hospital told Jianzhi Bureau that the phenomenon of hypoglycemic drugs was used as a weight loss needle. "China has not approved the indications of these drugs in obesity. At present, all use belongs to super -adaptable drugs or irregular medicines."

Many people have not paid attention to the side effects of the existence of GLP-1 agonist. Canada has warned the risk of pancreatic cancer related to Essean peptides. The US FDA disclosed in a bad incident report from July to September 2021: GLP-1 agonists such as Lichel peptide may cause gallbladder-related diseases.

The GLP-1 agonist is not available. According to the internationally unified regulatory requirements, the premise of treating obesity with GLP-1 agonist is to suffer from obesity patients with diabetes, and it must be used with other hypoglycemic drugs, and the BMI indicator that reflects the body's obesity must be more than 28.

Li Jianyu, an associate professor of the Department of Endocrinology Metabolism of Huaxi Hospital of Sichuan University, believes that although no serious drug adverse reactions are found at present, GLP-1 agonist drugs are abused in unsuitable people, and the side effects of losing weight may be difficult to expect or even affect normal life.

For obese people, the GLP-1 agonist may be a shortcut of successful weight loss, but it is necessary to use it correctly to get the best results. With the advancement of technology, there may be better weight loss drugs in the future, and this market will have huge potential.

Writing | Xiaomi

Edit ｜ Jiang Yun Jia Ting

Operation | Valley

Illustration | Visual China

- END -